Carlsmed, Inc. (CARL) - Net Assets
Based on the latest financial reports, Carlsmed, Inc. (CARL) has net assets worth $84.25 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($118.20 Million) and total liabilities ($33.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CARL equity financing ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $84.25 Million |
| % of Total Assets | 71.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Carlsmed, Inc. - Net Assets Trend (2023–2025)
This chart illustrates how Carlsmed, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Carlsmed, Inc. market cap and net worth.
Annual Net Assets for Carlsmed, Inc. (2023–2025)
The table below shows the annual net assets of Carlsmed, Inc. from 2023 to 2025. Also explore Carlsmed, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $98.87 Million | +239.98% |
| 2024-12-31 | $-70.63 Million | -53.11% |
| 2023-12-31 | $-46.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Carlsmed, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5389100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $199.67 Million | 201.96% |
| Total Equity | $98.87 Million | 100.00% |
Carlsmed, Inc. Competitors by Market Cap
The table below lists competitors of Carlsmed, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
$409.29 Million |
|
HANSEN TECHNOLOGIES LTD.
F:H2T
|
$409.41 Million |
|
Eik fasteignafélag hf
IC:EIK
|
$409.44 Million |
|
Solusi Bangun Indonesia Tbk PT
JK:SMCB
|
$409.59 Million |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
$409.20 Million |
|
Qinhuangdao Tianqin Equipment Manufacturing Co.Ltd.
SHE:300922
|
$409.11 Million |
|
Chengdu Dahongli Machinery Co Ltd
SHE:300865
|
$409.11 Million |
|
Cross Country Healthcare Inc
NASDAQ:CCRN
|
$409.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carlsmed, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -70,630,000 to 98,869,000, a change of 169,499,000.
- Net loss of 29,634,000 reduced equity.
- New share issuances of 105,384,000 increased equity.
- Other factors increased equity by 93,749,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.63 Million | -29.97% |
| Share Issuances | $105.38 Million | +106.59% |
| Other Changes | $93.75 Million | +94.82% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Carlsmed, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-10.38 | $15.23 | x |
| 2024-12-31 | $-4.26 | $15.23 | x |
| 2025-12-31 | $6.95 | $15.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carlsmed, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -58.67%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.32x
- Recent ROE (-29.97%) is below the historical average (-9.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -137.16% | 0.98x | 0.00x | $-14.29 Million |
| 2024 | 0.00% | -89.30% | 0.52x | 0.00x | $-17.19 Million |
| 2025 | -29.97% | -58.67% | 0.39x | 1.32x | $-39.52 Million |
Industry Comparison
This section compares Carlsmed, Inc.'s net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $287,272,347
- Average return on equity (ROE) among peers: -245.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $84.25 Million | 0.00% | 0.40x | $409.27 Million |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.53 Million |
| American Well Corp (AMWL) | $374.94 Million | -23.25% | 0.33x | $133.17 Million |
| Heartbeam Inc (BEAT) | $15.94 Million | -91.86% | 0.07x | $23.95 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-1.01 Million | 0.00% | 0.00x | $5.11 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $784.08 Million | -6.88% | 5.94x | $10.63 Billion |
| CareCloud, Inc. (CCLD) | $7.07 Million | -124.48% | 3.01x | $87.11 Million |
| Certara Inc (CERT) | $822.13 Million | -6.01% | 0.54x | $1.12 Billion |
| CareMax Inc (CMAX) | $505.37 Million | -1.32% | 0.29x | $381.50 |
| Claritev Corporation (CTEV) | $84.02 Million | -1958.81% | 60.30x | $555.59 Million |
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more